DekaBank Deutsche Girozentrale lifted its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 4.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,659,731 shares of the healthcare product maker's stock after purchasing an additional 116,452 shares during the period. Abbott Laboratories accounts for 0.7% of DekaBank Deutsche Girozentrale's portfolio, making the stock its 27th largest holding. DekaBank Deutsche Girozentrale owned 0.15% of Abbott Laboratories worth $348,746,000 at the end of the most recent reporting period.
Other hedge funds have also bought and sold shares of the company. Personal CFO Solutions LLC lifted its holdings in Abbott Laboratories by 0.5% during the 1st quarter. Personal CFO Solutions LLC now owns 17,560 shares of the healthcare product maker's stock valued at $2,329,000 after purchasing an additional 84 shares during the last quarter. Partners in Financial Planning boosted its holdings in shares of Abbott Laboratories by 37.5% during the 1st quarter. Partners in Financial Planning now owns 3,145 shares of the healthcare product maker's stock worth $417,000 after buying an additional 857 shares during the period. Valeo Financial Advisors LLC grew its stake in Abbott Laboratories by 2.6% in the 1st quarter. Valeo Financial Advisors LLC now owns 32,298 shares of the healthcare product maker's stock valued at $4,284,000 after buying an additional 809 shares during the last quarter. Stratos Investment Management LLC lifted its position in Abbott Laboratories by 228.4% during the first quarter. Stratos Investment Management LLC now owns 16,139 shares of the healthcare product maker's stock worth $2,141,000 after acquiring an additional 11,224 shares during the last quarter. Finally, Blackhawk Capital Partners LLC. grew its position in shares of Abbott Laboratories by 3.5% in the first quarter. Blackhawk Capital Partners LLC. now owns 27,600 shares of the healthcare product maker's stock valued at $3,661,000 after purchasing an additional 921 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.
Abbott Laboratories Price Performance
Shares of Abbott Laboratories stock traded up $0.05 on Wednesday, hitting $133.41. 4,613,653 shares of the company traded hands, compared to its average volume of 6,162,028. The stock has a market capitalization of $232.11 billion, a P/E ratio of 17.30, a price-to-earnings-growth ratio of 2.53 and a beta of 0.73. The business has a 50-day simple moving average of $133.49 and a 200 day simple moving average of $128.72. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.27 and a current ratio of 1.78. Abbott Laboratories has a 52 week low of $99.71 and a 52 week high of $141.23.
Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings data on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.07 by $0.02. The company had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.38 billion. Abbott Laboratories had a return on equity of 19.01% and a net margin of 31.89%. Research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.
Abbott Laboratories Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th will be issued a $0.59 dividend. This represents a $2.36 annualized dividend and a dividend yield of 1.77%. The ex-dividend date is Tuesday, July 15th. Abbott Laboratories's dividend payout ratio (DPR) is currently 30.61%.
Analyst Ratings Changes
ABT has been the topic of a number of research reports. Leerink Partners assumed coverage on Abbott Laboratories in a report on Monday, June 16th. They issued a "market perform" rating and a $143.00 price objective on the stock. Stifel Nicolaus raised their price target on shares of Abbott Laboratories from $135.00 to $145.00 and gave the stock a "buy" rating in a research report on Thursday, April 17th. Raymond James Financial boosted their price objective on shares of Abbott Laboratories from $132.00 to $142.00 and gave the company an "outperform" rating in a report on Thursday, April 17th. Barclays increased their price target on Abbott Laboratories from $158.00 to $159.00 and gave the stock an "overweight" rating in a research report on Thursday, April 17th. Finally, Wells Fargo & Company upped their target price on Abbott Laboratories from $136.00 to $147.00 and gave the company an "overweight" rating in a research report on Thursday, April 17th. Six equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and a consensus target price of $143.11.
View Our Latest Stock Report on Abbott Laboratories
Insider Activity at Abbott Laboratories
In related news, Director Sally E. Blount sold 2,600 shares of the company's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total value of $337,116.00. Following the completion of the transaction, the director owned 34,058 shares of the company's stock, valued at approximately $4,415,960.28. This represents a 7.09% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.46% of the stock is owned by insiders.
Abbott Laboratories Profile
(
Free Report)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Recommended Stories
Before you consider Abbott Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.
While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
